AI assistant
Sending…
GALECTIN THERAPEUTICS INC — Director's Dealing 2018
Jan 17, 2018
33422_dirs_2018-01-17_780978ba-db7e-4626-8a68-fa15211c855b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2018-01-15
Reporting Person: CALLICUTT JACK W (Chief Financial Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-01-15 | Stock option (right to buy) | $5.87 | A | 90000 | Acquired | 2028-01-15 | Common Stock (90000) | Direct |
Footnotes
F1: The options vest as follows: 25% immediately, 25% on June 30, 2018, and 50% on December 31, 2018.
More from GALECTIN THERAPEUTICS INC
Regulatory Filings
2026
May 15
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
Mar 31
Regulatory Filings
2026
Mar 31
Annual Report
2026
Mar 31
Director's Dealing
2026
Mar 17
Director's Dealing
2026
Mar 17
Regulatory Filings
2026
Mar 17
Director's Dealing
2026
Feb 9
Regulatory Filings
2026
Jan 21